These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15963926)

  • 1. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.
    Kreppel F; Gackowski J; Schmidt E; Kochanek S
    Mol Ther; 2005 Jul; 12(1):107-17. PubMed ID: 15963926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
    Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
    J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.
    Campos SK; Barry MA
    Virology; 2006 Jun; 349(2):453-62. PubMed ID: 16504233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biophysical targeting of adenovirus vectors for gene therapy.
    Silman NJ; Fooks AR
    Curr Opin Mol Ther; 2000 Oct; 2(5):524-31. PubMed ID: 11249755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.
    Corjon S; Wortmann A; Engler T; van Rooijen N; Kochanek S; Kreppel F
    Mol Ther; 2008 Nov; 16(11):1813-24. PubMed ID: 18714309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.
    Jönsson F; Hagedorn C; Kreppel F
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of PEGylated adenovirus vector with targeting ligand.
    Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
    Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus protein IX: a new look at an old protein.
    Parks RJ
    Mol Ther; 2005 Jan; 11(1):19-25. PubMed ID: 15585402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved gene delivery into neuroglial cells using a fiber-modified adenovirus vector.
    Joung I; Harber G; Gerecke KM; Carroll SL; Collawn JF; Engler JA
    Biochem Biophys Res Commun; 2005 Mar; 328(4):1182-7. PubMed ID: 15708001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and selection of targeted adenoviruses embodying optimized vector properties.
    Noureddini SC; Krendelshchikov A; Simonenko V; Hedley SJ; Douglas JT; Curiel DT; Korokhov N
    Virus Res; 2006 Mar; 116(1-2):185-95. PubMed ID: 16293334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.
    Campos SK; Parrott MB; Barry MA
    Mol Ther; 2004 Jun; 9(6):942-54. PubMed ID: 15194061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob.
    Miura Y; Yoshida K; Nishimoto T; Hatanaka K; Ohnami S; Asaka M; Douglas JT; Curiel DT; Yoshida T; Aoki K
    Gene Ther; 2007 Oct; 14(20):1448-60. PubMed ID: 17700705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications.
    Espenlaub S; Corjon S; Engler T; Fella C; Ogris M; Wagner E; Kochanek S; Kreppel F
    Hum Gene Ther; 2010 Sep; 21(9):1155-67. PubMed ID: 20384482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon.
    Kurachi S; Koizumi N; Sakurai F; Kawabata K; Sakurai H; Nakagawa S; Hayakawa T; Mizuguchi H
    Gene Ther; 2007 Feb; 14(3):266-74. PubMed ID: 17006548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX.
    de Vrij J; Uil TG; van den Hengel SK; Cramer SJ; Koppers-Lalic D; Verweij MC; Wiertz EJ; Vellinga J; Willemsen RA; Hoeben RC
    Gene Ther; 2008 Jul; 15(13):978-89. PubMed ID: 18323790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of recombinant adenovirus: site-directed mutagenesis of key asparagine residues in the hexon protein.
    Blanche F; Cameron B; Somarriba S; Maton L; Barbot A; Guillemin T
    Anal Biochem; 2001 Oct; 297(1):1-9. PubMed ID: 11567521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PEGylated adenovirus for targeted gene therapy.
    O'Riordan CR; Song A
    Methods Mol Biol; 2008; 434():133-60. PubMed ID: 18470643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted and shielded adenovectors for cancer therapy.
    Hedley SJ; Chen J; Mountz JD; Li J; Curiel DT; Korokhov N; Kovesdi I
    Cancer Immunol Immunother; 2006 Nov; 55(11):1412-9. PubMed ID: 16612598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells.
    Stachler MD; Bartlett JS
    Gene Ther; 2006 Jun; 13(11):926-31. PubMed ID: 16482202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcellular targeting of fiber- and hexon-modified adenovirus vectors across the brain microvascular endothelial cells in vitro.
    Laakkonen JP; Engler T; Romero IA; Weksler B; Couraud PO; Kreppel F; Kochanek S
    PLoS One; 2012; 7(9):e45977. PubMed ID: 23029348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.